|
 
- 积分
- 3053
- 威望
- 3053
- 包包
- 5595
|
Glance at last issue:, e2 _0 V$ U3 o8 a& X. _3 m) ]
: {8 A; p" |; |1 Q. u# l( t, R" {“You’ve got to remember, their whole mandate is commercialization. Let’s get those through and into the clinic so that we can demonstrate to the world that the [human embryonic stem cell] platform has value.”--William Caldwell, CEO of Massachusetts-based stem cell company Advanced Cell Technology (ACT)." G' ^0 @8 Q5 X/ S1 c
7 W1 C) x/ i; [“This study shows that the mature cells actually communicate back to the stem cells, changing their gene expression and influencing their behavior.”--Professor Doug Hilton from the Molecular Medicine division of Melbourne’s Walter and Eliza Hall Institute.- ?+ O3 O: U5 l& x
7 K3 G8 @0 R5 e# r“The stem cells, rather than being maintained in a ‘resting state’ until needed, were being told to continually cycle and produce mature blood cells. The stem cells were eventually exhausted and blood disorders developed because there were not enough stem cells to produce new red and white blood cells.”--Dr Carolyn de Graaf from the Molecular Medicine division of Melbourne’s Walter and Eliza Hall Institute.
5 ]+ H; ^6 w4 Y3 B4 Y6 `: p0 t
& u9 f) q0 M7 ?& B5 A"When we make a duck look like a cat, it may look like a cat and meow, but whether it still has feathers is an issue."--George Daley of Children's Hospital Boston and the Harvard Stem Cell Institute.) @) [3 B1 [( R
4 z7 S* ~ M8 K$ D- o“All the basic biology of the human eye and retina is the same as it is in the mouse. If we can get enough of the cells to grow and integrate, I think we’d go right into [trials with] humans.”--Derek van der Kooy, professor of molecular genetics at U of T and senior scientist at the McEwen Centre for Regenerative Medicine.
4 Y2 F8 U& C6 G# F' a5 k; \) h8 _& ?4 t, e# }8 e0 F3 w& x9 f
“Although labeling of stem cells with MRI is promising, there are some limitations. More optimal particles are needed that can be taken up without the need of potentially toxic agents. Also, there is the problem of particle dilution over time as cells divide. When grafted cells continue to proliferate, loss of signal occurs.”--Dr. Annelies Crabbe, from the Stem Cell Institute, Katholieke Universiteit Leuven.. O) c& r) F" K4 ?5 [, b. a. x
0 N. M9 s& v. d# [5 U"I have been wary of getting involved in biotech companies in last decades, because I really never saw the pragmatic utility of what certain discoveries offered. Here, I see a clear avenue of advance. It’s logical. It’s practical and it’s not pie-in-the-sky."--Robert A. Weinberg at the Massachusetts Institute of Technology and the Whitehead Institute for Biomedical Research." D; z) J7 ?/ f( M, [
7 V! X. Z: k( k7 n: \9 D
“The major problem with the cancer stem cell idea is that it is not supported by data—neither clinical observations nor basic science.”--Kornelia Polyak, M.D., Ph.D., a Dana-Farber researcher.0 m$ C, a; Y' A9 {6 _7 {
$ N. i( P- I" `“What's nice about the cancer stem cell hypothesis is it explains a lot of things, especially in the area of brain cancer, where I work, such as how you get brain cancer in the first place. A highly malignant cell with stem-like properties could account for the bizarre collection of different cell types found within the most deadly brain cancer, glioblastoma multiforme.”--Charles Stiles, Ph.D., co-chair of Dana-Farber's department of cancer biology./ Q2 t1 e' |! b- v! G
- ?" {2 U% J5 @( V
“We believe that it won't be possible to cure patients by targeting rare subpopulations of cells. We think you need to kill all the cells.”--Sean Morrison, Ph.D., who directs the Center for Stem Cell Biology at the University of Michigan.
4 d% B1 k; l( ?9 L! V: f% K3 n- k: d, i' D7 `! d) _
"This raises the possibility that, in the future, we may be able to modulate stem cell function when treating degenerative diseases or when performing cell therapies by altering the metabolism of the cells."--Sean Morrison, Ph.D., who directs the Center for Stem Cell Biology at the University of Michigan.
' W0 J5 v" `& [; K! ~, F
4 T" R. K+ u, w1 ^# O# y/ g"The beauty of our product development and manufacturing technology is that we can utilize it to develop and manufacture virtually any cell type from virtually any person that our customers select."--Bob Palay, CDI's chairman and chief executive officer, said in the statement.
/ u: \9 ~: A I) ?& J7 z6 k* r9 d. o, T
“Much of the top stem‐cell research being conducted today takes place outside the United States. To be an industry leader in this field, you have to be international, and we fully intend to fund and produce industry‐leading innovations.”--President and CEO Cindy Morrissey of Emerging Healthcare Solutions, Inc.0 j0 M1 o0 u9 i5 D% `- h
1 r* \8 c* k% V& G; f0 U“Our findings show that human iPS cells are not stable in culture, as was previously thought, and require reassessment of the chromosomal structure of these cells. Also, our work shows for the first time the gene expression changes that accompany these chromosomal aberrations found in the culture, paving the way for our beginning to understand the mechanism by which these changes occur. The chromosomal changes in these iPS cells require everyone to exercise great care in continuing to work with them, since these changes apparently will influence the differentiation potential and the tumorigenic risk of these cells.”--Dr. Nissim Benvenisty, professor of cancer research at the Hebrew University of Jerusalem.; }7 B0 w. M! G$ i s; C
7 N i( J% m' u0 c5 |"Basically we gave back the patient's own tissue and cells in a very high concentration -- about nine times higher than the body produces. It's kind of like flipping on a switch that allows the patient to heal more quickly...Platelets and stem cells play a significant role in the repair and regeneration of connective tissue. They are a natural source of growth factors. The great thing about this technology is we can do it instantly – obtain the donation, separate out the platelets and stem cells, and transplant it back – all while the patient is in the operating room."--Dr. Paul Bishop of Morris Hospital.
. t( z% j. `; ?6 m) W, N9 y2 b$ {1 t' F4 K u4 @
"We now know that it does things like recruit your own stem cells to the site. It changes the body's immune response from inflammatory to constructive remodeling. Rather than harvesting or manipulating stem cells through a complex process outside the body, ECM recruits them from the inside."--Stephen Badylak, DVM, PhD, MD, professor in the Department of Surgery, University of Pittsburgh, and director of the Center for Pre-Clinical Tissue Engineering within the McGowan Institute for Regeneration Medicine.
! @% g( s8 M! _
2 I; U3 l6 \' M7 @7 H% p6 Q& e3 j8 l+ A% h6 c
This issue:: K2 G+ x& K! ]8 S( C! T$ h+ j
|
附件: 你需要登录才可以下载或查看附件。没有帐号？注册
-
总评分: 威望 + 10
包包 + 20
查看全部评分
|
发表于 2010-12-8 18:27
